The Motley Fool
31 Oct 2026, 14:17 UTC · 1h ago
Is AbbVie a Buy After Its Latest Earnings Report?
Impact · against what's priced in
The earnings report confirms the market's existing thesis that Skyrizi and Rinvoq are successfully replacing Humira's lost revenue. Because the price already requires a ~11% CAGR and strong immunology performance, the modest guidance raise and revenue beat provide little incremental catalyst.
- ABBV+0.00
Already priced in
- The price assumes
SKYRIZI and RINVOQ replacing HUMIRA's lost revenue
The combined $8.5 billion in revenue from Skyrizi and Rinvoq, now 48.7% of total sales, validates the market's existing assumption that these drugs are effectively offsetting the decline of Humira to $683 million.
What ABBV's price assumes · Sep 4
Top 2 movers · tap to explore
